• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

    1.480 +0.020 (+1.37%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 890,706
    Open 1.460
    Bid (Size) 1.450 (200)
    Ask (Size) 1.500 (2,000)
    Prev. Close 1.460
    Today's Range 1.440 - 1.500
    52wk Range 1.175 - 2.700
    Shares Outstanding 52,346,231
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Autolus Therapeutics to Participate in Upcoming Investor Conferences
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
    From Autolus Therapeutics plc
    Via GlobeNewswire

    Performance

    YTD
    -20.9%
    -20.9%
    1 Month
    -6.3%
    -6.3%
    3 Month
    -5.1%
    -5.1%
    6 Month
    -3.3%
    -3.3%
    1 Year
    -36.5%
    -36.5%

    More News

    Read More
    News headline image
    Autolus (AUTL) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Autolus Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus ↗
    Via Chartmill
    News headline image
    Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
    From Autolus Therapeutics plc
    Via GlobeNewswire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
    Via Investor Brand Network
    Topics Intellectual Property
    Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
    Via Investor Brand Network
    News headline image
    Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Participate in Upcoming Investor Conferences
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Participate in Upcoming Investor Conferences
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
    From Cellares Corp
    Via Business Wire
    News headline image
    Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    News headline image
    AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK ↗
    Via Stocktwits

    Frequently Asked Questions

    Is Autolus Therapeutics plc - American Depositary Shares publicly traded?
    Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.
    What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?
    Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?
    The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market
    What is the current price of Autolus Therapeutics plc - American Depositary Shares?
    The current price of Autolus Therapeutics plc - American Depositary Shares is 1.480
    When was Autolus Therapeutics plc - American Depositary Shares last traded?
    The last trade of Autolus Therapeutics plc - American Depositary Shares was at 06/10/26 04:00 PM ET
    What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?
    The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 77.47M
    How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?
    Autolus Therapeutics plc - American Depositary Shares has 77M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.